Thymosin alpha-1 versus interferon alpha for chronic hepatitis B: meta-analysis
At end of treatment, thymosin alpha-1 was not clearly superior; at 6-month post-treatment follow-up, pooled virological, biochemical and complete responses favored thymosin alpha-1.
What this study tells us
This study reviewed or combined evidence from multiple studies. It can show the overall direction of a field, but its conclusion still depends on the quality and relevance of the studies it included.
People with chronic hepatitis B
n=199
At end of treatment, thymosin alpha-1 was not clearly superior; at 6-month post-treatment follow-up, pooled virological, biochemical and complete responses favored thymosin alpha-1.
Only four small RCTs; mostly HBeAg-negative patients; older treatment landscape.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
At end of treatment, thymosin alpha-1 was not clearly superior; at 6-month post-treatment follow-up, pooled virological, biochemical and complete responses favored thymosin alpha-1.